Physician profile
Ghulam Mujtaba
NPI 1821277187
$9,282.52
in general payments reported to CMS, 2019-2025
43 companies · $1,899 in 2025
The $1,899 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $459 · 2020: $548 · 2021: $1,011 · 2022: $1,816 · 2023: $1,370 · 2024: $2,180 · 2025: $1,899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,448.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,448.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,804.80 | 2020-2025 | |
| Janssen Biotech, INC. | $839.93 | 2022-2025 | Stelara, Tremfya, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $756.23 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Genzyme Corporation | $639.51 | 2022-2025 | |
| Ironwood Pharmaceuticals, INC | $429.92 | 2020-2024 | Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $378.93 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Ferring Pharmaceuticals INC. | $342.35 | 2019-2023 | Rebyota |
| Gilead Sciences, INC. | $312.16 | 2019-2025 | |
| Orphalan INC | $270.15 | 2024-2025 | Cuvrior |
| Abiomed | $216.65 | 2025 | |
| Braintree Laboratories, INC. | $215.65 | 2019-2024 | Sutab, Suflave |
| Aimmune Therapeutics, INC. | $208.83 | 2024-2025 | Zenpep, Vowst |
| Celgene Corporation | $201.00 | 2021-2024 | Zeposia |
| Redhill Biopharma INC. | $189.73 | 2021-2023 | Talicia, Movantik, Aemcolo |
| Intercept Pharmaceuticals, INC. | $132.58 | 2020-2024 | Ocaliva |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ghulam Mujtaba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.